sublingual tirzepatide vs injection Tirzepatide Tablets vs. Injections Compounded Tirzepatide: Oral Vs. Injectable

10 mg injected subcutaneously once weekly in pediatric patients

Important safety considerations include a boxed warning for thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2), and warnings for pancreatitis, gallbladder disease, acute kidney injury, and severe gastrointestinal disease

These effects are typically most pronounced during the first few weeks of treatment and often diminish as the body adapts to the medication

According to one study, HbA1c reductions were greater with the 10 mg and 15 mg doses of tirzepatide versus the lower doses